Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Shelter Pharma revenue climbs 44% to ₹73.13 crore

The Ahmedabad-based firm grew annual net profit by 25% to ₹9.03 crore for FY26, as the board appointed a new internal auditor.


Mkt cap₹50.51 cr
P/E6.98×
ROE16.94%
Debt / eq.0.02
Div yld1.17%
₹73.13 cr Annual revenue for the fiscal year ended March 31, 2026.

What's new

  • Annual revenue rose 44% to ₹73.13 crore.
  • Net profit increased 25% to ₹9.03 crore.
  • CA Ismail Ibrahimbhai Lakhani appointed as internal auditor for FY27.

Why this matters

For a company with a market valuation of ₹51 crore, this growth shows meaningful scaling. The bottom-line expansion confirms that the firm is managing its profitability alongside its top-line gains.

What we're watching

  • Whether the company maintains this growth pace in FY27.
  • The impact of the new internal auditor on financial reporting processes.
  • Any further expansion plans for the current fiscal year.

The full read

Shelter Pharma delivered a strong performance for the fiscal year ended March 31, 2026. Annual revenue jumped 44% to ₹73.13 crore, while net profit grew 25% to ₹9.03 crore from ₹7.24 crore in the previous year. Earnings per share also ticked up to ₹6.57 from ₹6.26.

For a company with a market valuation of just ₹51 crore, these results indicate rapid operational expansion. The board also moved to strengthen its oversight by appointing CA Ismail Ibrahimbhai Lakhani as the internal auditor for FY27. These figures provide a clear picture of the company’s recent scaling efforts and its ability to maintain bottom-line stability while growing its top line.

Growth is clear. The next test is whether this momentum persists into the current fiscal year.

Questions answered

How did Shelter Pharma's profit compare to the previous year?
Net profit reached ₹9.03 crore for FY26, up from ₹7.24 crore in the previous fiscal year.
What was the change in earnings per share?
Earnings per share rose to ₹6.57 for FY26, compared to ₹6.26 in the prior year.
Who is the new internal auditor?
The board appointed CA Ismail Ibrahimbhai Lakhani to serve as the internal auditor for the 2026-27 financial year.
What is the company's current market valuation?
Shelter Pharma has a market valuation of approximately ₹51 crore.
Mentioned: Shelter Pharma · Ismail Ibrahimbhai Lakhani
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.